MLX-7006

LEHI, Utah., Sept. 12, 2024 /PRNewswire/ -- Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the remarkable preclinical results of its oral small molecule GLP-1 agonist, BLX-7006. In a recent study, BLX-7006 demonstrated significant weight loss efficacy, establishing it as a potential breakthrough in the global fight against obesity. In a controlled diet-induced obesity (DIO) study conducted on mice, BLX-7006 achieved an average weight reduction of 15% over a 28-day period. These promising results are comparable to those seen with semaglutide, one of the most effective GLP-1 agonists currently available. However, BLX-7006 sets itself apart with its convenient oral administration and small molecule structure, making it a transformative prospect in weight management therapeutics. "We are thrilled with the positive outcomes from our preclinical studies with BLX-7006," said Dr. Hariprasad Vankayalapati, Chief Scientific Officer at Biolexis. "Our goal is to bring forward an innovative weight loss therapy that offers the same, or better, efficacy as injectable treatments but in a more convenient oral form. This is a significant step forward for patients seeking safer, more accessible treatment options." Key Highlights of BLX-7006: Oral Administration: Unlike current GLP-1 agonist treatments, which require injection, BLX-7006 is taken orally, offering greater convenience and potentially improving patient adherence. Small Molecule Technology: As a small molecule, BLX-7006 avoids the complexities and high costs associated with peptide-based drugs. This could streamline manufacturing processes, reduce costs, and improve drug stability. Reduced Side Effects: Pre-toxicology data suggest BLX-7006 is well tolerated with no observed organ toxicities when compared to current weight loss therapies, making it safer for long-term use. In addition to weight loss, BLX-7006 demonstrates promising efficacy in Type 2 Diabetes animal models. Keith Marmer, Chief Business Officer at Biolexis, commented, "BLX-7006 represents a significant leap forward in weight loss treatment. It's oral formulation and small molecule composition could offer patients an easier, more comfortable experience while delivering highly effective weight loss results. We're excited to advance this promising therapy through IND-enabling studies, with human clinical trials scheduled for early 2025. Biolexis is excited to deliver a weight loss treatment that is widely accessible and significantly lower cost than what is currently available today." Biolexis Therapeutics is dedicated to addressing the global obesity epidemic through scientific innovation. The company continues to explore ways to deliver effective, accessible, and safe weight loss treatments to patients around the world. For more information about Biolexis and its cutting-edge research, visit . About Biolexis Biolexis Therapeutics is a privately held biopharmaceutical company committed to developing next-generation small-molecule therapies for metabolic diseases, including obesity. The company is focused on delivering innovative solutions to unmet medical needs through advanced research and development. SOURCE Biolexis Therapeutics Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AMERICAN FORK, Utah, June 21, 2024 /PRNewswire/ -- Biolexis, a pioneering biopharmaceutical company, is proud to announce the presentation of two significant abstracts at the upcoming American Diabetes Association conference on June 21-24, 2024. The abstracts, titled "Discovery of a Potent, Orally Efficacious Small Molecule Agonist of Glucagon-Like Peptide-1 (GLP-1) Receptor" (Abstract 1139-P) and "Development of MLX-0871, a Potent, Isoform-Selective, Orally Available AMPK Activator, Displays Efficacy in Obese and Type 2 Diabetes Models" (Abstract 1145-P), showcase Biolexis' innovative approach to addressing critical metabolic diseases. The first abstract, 1139-P, details the discovery of MLX-7006, a potent and orally efficacious small molecule agonist of the GLP-1 receptor. This groundbreaking compound demonstrates significant potential in the treatment of metabolic disorders, offering a new avenue for therapeutic intervention. The second abstract, 1145-P, focuses on MLX-0871, an isoform-selective, orally available AMPK activator. This compound has shown remarkable efficacy in preclinical models of obesity and type 2 diabetes, highlighting its promise as a novel treatment for these widespread conditions. Dr. Hariprasad Vankayalapati, M.Pharm, PhD, Co-Founder and Chief Scientific Officer of Biolexis, expressed his enthusiasm for the progress of these novel therapies. "We are incredibly excited about the development of MLX-0871 and MLX-7006. These oral small molecules represent significant advancements in our mission to develop innovative treatments for metabolic diseases." Dr. Vankayalapati's co-founder, Dr. David Bearss, PhD added "The efficacy demonstrated in our preclinical studies is promising, and we look forward to advancing these compounds through clinical development. We anticipate bringing each of these assets to the clinic by the 2nd quarter of early 2025." Both abstracts will be presented on Monday, June 24th, providing attendees with an in-depth look at the pioneering research and promising results achieved by the Biolexis team. For more information about these presentations, please visit the ADA website. About Biolexis Therapeutics Biolexis is dedicated to addressing the urgent global challenges posed by diabetes, obesity, and other metabolic disorders. Leveraging cutting-edge technologies and a deep commitment to scientific innovation, we are focused on transforming the landscape of treatment options available to patients worldwide. Our robust pipeline is driven by a relentless pursuit of novel therapeutic approaches, aimed at not only managing but potentially reversing the devastating effects of these prevalent and complex conditions. SOURCE Biolexis Therapeutics Inc